BACKGROUND: Aromatase inhibitors (AIs) frequently lead to the AI-induced musculoskeletal syndrome (AIMSS). Looking into its pathophysiology, 6 months of AI therapy thickens the tendon sheath with intra-articular fluid (IAF) retention and loss of grip strength. We here report 24-month follow-up data. PATIENTS AND METHODS: A prospective cohort study of 33 postmenopausal breast cancer patients received adjuvant endocrine therapy; 27 received an AI and 6 received tamoxifen. At baseline, 6 and 24 months patients had a rheumatologic examination, including a grip strength test, and magnetic resonance imaging of both hands and wrists. The primary end point was tenosynovial changes; secondary end points were changes in morning stiffness, grip strength and IAF. RESULTS: Twenty-three AI and 5 tamoxifen patients completed all investigations. Between month 6 and 24, IAF further increased in AI users (P = 0.04) but not in tamoxifen users, and grip strength further decreased in both groups. The worsened tenosynovial changes were strongly correlated with a decrease in grip strength. At 24 months, morning stiffness continued to be present in over a third of AI users. CONCLUSION: AIMSS represents a substantial problem in breast cancer patients. It is associated with tenosynovial changes, IAF retention, joint stiffness and loss of grip strength that do not improve with prolonged use.
BACKGROUND: Aromatase inhibitors (AIs) frequently lead to the AI-induced musculoskeletal syndrome (AIMSS). Looking into its pathophysiology, 6 months of AI therapy thickens the tendon sheath with intra-articular fluid (IAF) retention and loss of grip strength. We here report 24-month follow-up data. PATIENTS AND METHODS: A prospective cohort study of 33 postmenopausal breast cancerpatients received adjuvant endocrine therapy; 27 received an AI and 6 received tamoxifen. At baseline, 6 and 24 months patients had a rheumatologic examination, including a grip strength test, and magnetic resonance imaging of both hands and wrists. The primary end point was tenosynovial changes; secondary end points were changes in morning stiffness, grip strength and IAF. RESULTS: Twenty-three AI and 5 tamoxifenpatients completed all investigations. Between month 6 and 24, IAF further increased in AI users (P = 0.04) but not in tamoxifen users, and grip strength further decreased in both groups. The worsened tenosynovial changes were strongly correlated with a decrease in grip strength. At 24 months, morning stiffness continued to be present in over a third of AI users. CONCLUSION: AIMSS represents a substantial problem in breast cancerpatients. It is associated with tenosynovial changes, IAF retention, joint stiffness and loss of grip strength that do not improve with prolonged use.
Authors: Arlene Chan; R De Boer; A Gan; P Willsher; R Martin; Y Zissiadis; K Miller; A Bauwens; D Hastrich Journal: Support Care Cancer Date: 2017-07-09 Impact factor: 3.603
Authors: Jennifer Y Sheng; Amanda L Blackford; Aditya Bardia; Raghunandan Venkat; Gedge Rosson; Jon Giles; Daniel F Hayes; Stacie C Jeter; Zhe Zhang; Jill Hayden; Anne Nguyen; Anna Maria Storniolo; Karineh Tarpinian; Norah Lynn Henry; Vered Stearns Journal: Breast Cancer Res Treat Date: 2019-05-11 Impact factor: 4.872
Authors: Alice C Shapiro; Susan A Adlis; Kim Robien; Mark N Kirstein; Shuang Liang; Sara A Richter; Rachel E Lerner Journal: Breast Cancer Res Treat Date: 2016-02-11 Impact factor: 4.872
Authors: Kate E Roberts; India T Adsett; Kirsty Rickett; Sophie M Conroy; Mark D Chatfield; Natasha E Woodward Journal: Cochrane Database Syst Rev Date: 2022-01-10
Authors: Jason D Robarge; Djane B Duarte; Behzad Shariati; Ruizhong Wang; David A Flockhart; Michael R Vasko Journal: Exp Neurol Date: 2016-04-09 Impact factor: 5.330
Authors: Jessica A Martinez; Mihra S Taljanovic; Russell S Witte; Andres A Nuncio Zuniga; Betsy C Wertheim; C Kent Kwoh; Brian A Goldstein; Denise J Roe; Pavani Chalasani Journal: J Ultrason Date: 2021-03-08